Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
For Full Prescribing and Safety Information for FIRDAPSE, please visit www.firdapse.com.
Investing4d
FIRDAPSE now available in Japan for muscle weakness
FIRDAPSE® is currently the only U.S. FDA-approved therapy for LEMS in adults and pediatric patients six years of age and older. The launch in Japan is part of Catalyst's mission to expand patient ...
Catalyst announces sub-licensee pharma launches FIRDAPSE in Japan
Catalyst Pharmaceuticals (CPRX) reported that its sub-licensee in Japan, DyDo Pharma has launched FIRDAPSE Tablets 10 mg in Japan for the ...
FIRDAPSE now available in Japan for muscle weakness
CORAL GABLES, Fla. - Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), a pharmaceutical company demonstrating excellent financial ...
Nasdaq4d
Catalyst's FIRDAPSE Approved For Use In Japan, Offering New Hope For LEMS Patients
(RTTNews) - Catalyst Pharmaceuticals, Inc. (CPRX), a commercial-stage biopharmaceutical company, Tuesday announced that its sub-licensee, DyDo Pharma, has launched FIRDAPSE or amifampridine ...
Nasdaq4d
Catalyst Pharmaceuticals Sub-Licensee DyDo Pharma Launches FIRDAPSE® in Japan for Lambert-Eaton Myasthenic Syndrome
Catalyst Pharmaceuticals, Inc. announced that its sub-licensee, DyDo Pharma, has launched FIRDAPSE® (amifampridine) Tablets 10 mg in Japan, aimed at improving muscle weakness in patients with ...
Morningstar4d
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
"We are pleased that our sub-licensee, DyDo, has launched FIRDAPSE in Japan. We believe in health equity, and this launch is a testament to our ongoing efforts to increase patient access to life ...